Bass returns funds but vows to continue pharma fight

24-02-2016

Bass returns funds but vows to continue pharma fight

Svetlana Lukienko / Shutterstock.com

Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review (IPR) challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.


Kyle Bass; PTAB; Vimovo; IPR; Coalition for Affordable Drugs; Pozen

LSIPR